View All

Tesaro’s Zejula; Mylan on EpiPen; Ohio sues drugmakers; ATUM, Horizon Discovery Announce deal

Tesaro and its new med Zejula are on the block, but bidders aren't rushing in Just ahead of the year’s biggest download of cancer data, the maker of a closely watched drug has put itself up for sale, according to The Wall Street Journal. That’s Tesaro, whose PARP inhibitor Zejula won FDA approval in March. That med ...

Find More

Pfizer uses; FDA approves; EMA approves; Mylan launches

For Inflectra launch, Pfizer uses 'hybrid model' to home in on HCPs Pfizer hit the market with Inflectra, a biosimilar of Johnson & Johnson's Remicade. And with the launch came not only the beginning of a new class of copycats, but a new way to go to market. Each biosimilar, even versions of the same biologic—wh...

Find More

The Road Less Travelled: EpiPen’s Pricing Policy

Mylan’s EpiPen is used as a lifesaver to threatening allergic reactions. It mitigates or reverses allergic reactions including abrupt blocking of airways and swollen legs, chest or neck.  In late 2007, Mylan acquired the rights to sell EpiPen, an invention of the 1970s. Even its inventor Sheldon Kaplan did not ...

Find More

NATCO Pharma surges; AstraZeneca falls; US patent office rules

NATCO Pharma surges 7% post successful Establishment Inspection Report for Chennai Plant NATCO pharma has reached a new high of Rs. 703 on the National Stock Exchange (NSE) as the drug maker revealed the successful Establishment Inspection Report (EIR) for Chennai Plant. The U.S. Food and Drug Administration (FDA) h...

Find More